טוען...
GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side
Diabetic kidney disease (DKD), one of the most common and severe microvascular complications of diabetes, is the leading cause of chronic kidney disease and end-stage kidney disease worldwide. Since the development of renin-angiotensin system inhibition nearly three decades ago, no new therapeutic a...
שמור ב:
| הוצא לאור ב: | Am J Physiol Renal Physiol |
|---|---|
| Main Authors: | , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
American Physiological Society
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6337002/ https://ncbi.nlm.nih.gov/pubmed/30110568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1152/ajprenal.00211.2018 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|